Goldman Sachs’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.4M | Sell |
988,416
-79,715
| -7% | -$2.17M | ﹤0.01% | 2012 |
|
|
2025
Q4 | $29M | Buy |
1,068,131
+38,671
| +4% | +$1.02M | ﹤0.01% | 2008 |
|
|
2025
Q3 | $26.6M | Buy |
1,029,460
+301,956
| +42% | +$7M | ﹤0.01% | 1972 |
|
|
2025
Q2 | $14.8M | Buy |
727,504
+31,497
| +5% | +$613K | ﹤0.01% | 2390 |
|
|
2025
Q1 | $12.6M | Sell |
696,007
-506,446
| -42% | -$11.3M | ﹤0.01% | 2470 |
|
|
2024
Q4 | $30.4M | Sell |
1,202,453
-633,390
| -35% | -$17.2M | ﹤0.01% | 1730 |
|
|
2024
Q3 | $62.4M | Buy |
1,835,843
+961,650
| +110% | +$36.6M | 0.01% | 1080 |
|
|
2024
Q2 | $32.4M | Buy |
874,193
+309,390
| +55% | +$11.7M | 0.01% | 1486 |
|
|
2024
Q1 | $23.7M | Buy |
564,803
+127,044
| +29% | +$5.22M | ﹤0.01% | 1693 |
|
|
2023
Q4 | $17.4M | Buy |
437,759
+25,925
| +6% | +$762K | ﹤0.01% | 2032 |
|
|
2023
Q3 | $11.3M | Sell |
411,834
-31,066
| -7% | -$974K | ﹤0.01% | 2287 |
|
|
2023
Q2 | $15M | Buy |
442,900
+82,727
| +23% | +$2.79M | ﹤0.01% | 2095 |
|
|
2023
Q1 | $13M | Sell |
360,173
-89,411
| -20% | -$3.86M | ﹤0.01% | 2187 |
|
|
2022
Q4 | $20M | Sell |
449,584
-214,847
| -32% | -$7.67M | ﹤0.01% | 1962 |
|
|
2022
Q3 | $18.7M | Buy |
664,431
+224,719
| +51% | +$6.89M | ﹤0.01% | 1927 |
|
|
2022
Q2 | $11.9M | Buy |
439,712
+136,293
| +45% | +$3.96M | ﹤0.01% | 2341 |
|
|
2022
Q1 | $10.3M | Buy |
303,419
+49,205
| +19% | +$1.57M | ﹤0.01% | 2661 |
|
|
2021
Q4 | $9.82M | Sell |
254,214
-53,465
| -17% | -$2.33M | ﹤0.01% | 2787 |
|
|
2021
Q3 | $16.6M | Sell |
307,679
-30,376
| -9% | -$1.43M | ﹤0.01% | 2247 |
|
|
2021
Q2 | $11.3M | Sell |
338,055
-130,826
| -28% | -$3.59M | ﹤0.01% | 2575 |
|
|
2021
Q1 | $9.66M | Sell |
468,881
-173,422
| -27% | -$3.98M | ﹤0.01% | 2595 |
|
|
2020
Q4 | $11.3M | Buy |
642,303
+539,046
| +522% | +$9.7M | ﹤0.01% | 2365 |
|
|
2020
Q3 | $1.53M | Buy |
+103,257
| New | +$1.21M | ﹤0.01% | 3766 |
|
|
2019
Q1 | – | Sell |
-3,369
| Closed | -$10K | – | 5170 |
|
|
2018
Q4 | $10K | Sell |
3,369
-31,797
| -90% | -$156K | ﹤0.01% | 5173 |
|
|
2018
Q3 | $238K | Sell |
35,166
-98,389
| -74% | -$689K | ﹤0.01% | 4821 |
|
|
2018
Q2 | $1.01M | Buy |
133,555
+102,778
| +334% | +$1.37M | ﹤0.01% | 4066 |
|
|
2018
Q1 | $1.07M | Buy |
30,777
+11,413
| +59% | +$442K | ﹤0.01% | 4004 |
|
|
2017
Q4 | $825K | Sell |
19,364
-6,096
| -24% | -$261K | ﹤0.01% | 4460 |
|
|
2017
Q3 | $1.09M | Buy |
25,460
+10,957
| +76% | +$411K | ﹤0.01% | 4500 |
|
|
2017
Q2 | $537K | Sell |
14,503
-4,192
| -22% | -$185K | ﹤0.01% | 5037 |
|
|
2017
Q1 | $1.01M | Buy |
18,695
+164
| +0.9% | +$8.54K | ﹤0.01% | 4367 |
|
|
2016
Q4 | $984K | Buy |
18,531
+4,369
| +31% | +$249K | ﹤0.01% | 4465 |
|
|
2016
Q3 | $858K | Sell |
14,162
-14,590
| -51% | -$909K | ﹤0.01% | 4557 |
|
|
2016
Q2 | $1.89M | Sell |
28,752
-1,279
| -4% | -$81.2K | ﹤0.01% | 3667 |
|
|
2016
Q1 | $1.7M | Buy |
30,031
+10,073
| +50% | +$1.13M | ﹤0.01% | 3629 |
|
|
2015
Q4 | $4.69M | Buy |
19,958
+3,015
| +18% | +$657K | ﹤0.01% | 2882 |
|
|
2015
Q3 | $2.68M | Sell |
16,943
-8,393
| -33% | -$2.38M | ﹤0.01% | 3493 |
|
|
2015
Q2 | $9.58M | Buy |
25,336
+4,486
| +22% | +$1.78M | ﹤0.01% | 2364 |
|
|
2015
Q1 | $8.72M | Sell |
20,850
-1,722
| -8% | -$616K | ﹤0.01% | 2411 |
|
|
2014
Q4 | $6.18M | Buy |
22,572
+5,606
| +33% | +$1.39M | ﹤0.01% | 2792 |
|
|
2014
Q3 | $3.3M | Buy |
16,966
+2,077
| +14% | +$453K | ﹤0.01% | 3427 |
|
|
2014
Q2 | $3.65M | Sell |
14,889
-559
| -4% | -$126K | ﹤0.01% | 3368 |
|
|
2014
Q1 | $4.09M | Buy |
15,448
+715
| +5% | +$274K | ﹤0.01% | 3248 |
|
|
2013
Q4 | $5.35M | Buy |
14,733
+1,923
| +15% | +$741K | ﹤0.01% | 3009 |
|
|
2013
Q3 | $6.81M | Buy |
12,810
+4,317
| +51% | +$1.48M | ﹤0.01% | 2628 |
|
|
2013
Q2 | $1.99M | Buy |
+8,493
| New | +$1.67M | ﹤0.01% | 3735 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Goldman Sachs's CLDX Position: Q1 2026 in Review
Goldman Sachs reduced its Celldex Therapeutics (CLDX) stake by 7.5% in Q1 2026, selling an estimated $2.17M and leaving 988,416 shares worth $31.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.
Goldman Sachs first reported a position in CLDX in Q2 2013 and has held it in 46 quarters since. The position peaked at $62.4M in Q3 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Goldman Sachs held 988,416 shares of Celldex Therapeutics worth $31.4M as of Q1 2026.
- Goldman Sachs sold 79,715 Celldex Therapeutics shares in Q1 2026, an estimated $2.17M.
- Celldex Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2012 holding.
- Goldman Sachs first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 46 quarters since.
- Goldman Sachs's Celldex Therapeutics position peaked at $62.4M in Q3 2024.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.